Preface
Shares of Neurocrine Biosciences (NBIX) are up nearly 40% since I published the article, in December 2018, citing my belief that shares of NBIX would see $100 again. At that time, Neurocrine had revealed disappointing data in Tourette's and traded in the low $70s. Since then, pipeline developments and Ingrezza earnings beats have buoyed shares considerably:
The following article will update investors on the most recent earnings beat and upcoming catalysts.
Ingrezza Beats Expectations
Neurocrine announced recently that Ingrezza procured $181M in revenue for the last quarter (Q2), beating expectations ($150M)